Rhythm Biosciences Informe acción ASX:RHY Capitalización de mercado
AU$32.3m
Rhythm Biosciences Limited
Informe acción ASX:RHY
Capitalización de mercado: AU$32.3m
Resumen de acción RHY Rhythm Biosciences Limited, empresa de diagnósticos médicos, ofrece análisis de sangre para la detección de cánceres en Australia.
Recompensas Análisis de riesgos + 2 riesgos adicionales
Ver todos los controles de riesgos Competidores de Rhythm Biosciences Limited Historial de precios y rendimiento
Resumen de todos los máximos históricos, cambios y caídas de precios de Rhythm Biosciences Precios históricos de las acciones Precio actual de la acción AU$0.13 Máximo en las últimas 52 semanas AU$0.23 Mínimo de 52 semanas AU$0.042 Beta 2.42 1Cambio en 1 mes 31.31% Variación en 3 meses 83.10% Cambio de 1 año -38.10% 3Variación en 3 años -93.26% Variación en 5 años -18.75% Variación desde la OPV -60.00%
Noticias y actualizaciones recientes
Rhythm Biosciences Ltd Appoints Gavin Fox-Smith as Independent Non-Executive Director Effective 2 December 2024 Nov 11
Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024 Sep 10
New minor risk - Share price stability Sep 06
New major risk - Financial position Aug 31
New major risk - Shareholder dilution Mar 31
New minor risk - Shareholder dilution Mar 26 Ver más actualizaciones
Rhythm Biosciences Ltd Appoints Gavin Fox-Smith as Independent Non-Executive Director Effective 2 December 2024 Nov 11
Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024 Sep 10
New minor risk - Share price stability Sep 06
New major risk - Financial position Aug 31
New major risk - Shareholder dilution Mar 31
New minor risk - Shareholder dilution Mar 26 Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million. Mar 22
Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million. Feb 09
Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director Dec 29
Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024 Dec 14
New major risk - Share price stability Dec 07
Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans? Dec 06
New minor risk - Share price stability Oct 12
New minor risk - Shareholder dilution Sep 13
Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023 Sep 01
New minor risk - Financial data availability Aug 26
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate Aug 09
Executive Chairman recently bought AU$248k worth of stock May 16
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely Apr 11
Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director Jan 31
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation Dec 02
Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited Nov 29
Less than half of directors are independent Nov 16
Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022 Oct 31 Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer
Executive Chairman recently sold AU$6.5m worth of stock Sep 10
Executive Chairman exercised options to buy AU$459k worth of stock. Aug 31
Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021) Aug 30
Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021) Aug 30
Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers Jul 19
Less than half of directors are independent Apr 27
Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ® Apr 04
Rhythm Biosciences Ltd Announces Executive Changes Feb 25
Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding Jan 06
Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7) Sep 23
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely Jul 19
Non-Executive Director David White has left the company Jul 15
Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial Jun 16
Rhythm Biosciences Betters ColoSTAT Results May 08
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation Mar 03
New 90-day high: AU$1.64 Mar 01
Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site Feb 11
New 90-day high: AU$1.56 Feb 10
Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites Jan 20
New 90-day high: AU$1.38 Jan 15
New 90-day high: AU$0.88 Dec 31
Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit Dec 04
Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares? Dec 03
New 90-day high: AU$0.28 Nov 10
New 90-day high: AU$0.21 Sep 24
Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial Sep 24
New 90-day high - AU$0.20 Sep 15
Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million. Aug 29
Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding Jul 23 Rentabilidad de los accionistas RHY AU Healthcare Mercado AU 7D 30.0% 3.1% 1.1% 1Y -38.1% 0.1% 18.3%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Los resultados de RHY fueron inferiores a los de la industria Australian Healthcare, que obtuvo un rendimiento del 0.1% el año pasado.
Rentabilidad vs. Mercado: RHY obtuvo unos resultados inferiores a los del mercado Australian, que fueron del 18.3% el año pasado.
Volatilidad de los precios Is RHY's price volatile compared to industry and market? RHY volatility RHY Average Weekly Movement 19.1% Healthcare Industry Average Movement 4.9% Market Average Movement 8.4% 10% most volatile stocks in AU Market 17.5% 10% least volatile stocks in AU Market 3.5%
Precio estable de las acciones: El precio de las acciones de RHY ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de RHY(19%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Australian.
Acerca de la empresa Rhythm Biosciences Limited, empresa de diagnósticos médicos, ofrece análisis de sangre para la detección de cánceres en Australia. Desarrolla ColoSTAT, un análisis de sangre para la detección precoz del cáncer colorrectal. Rhythm Biosciences Limited se constituyó en 2017 y tiene su sede en Parkville (Australia).
Mostrar más Resumen de fundamentos de Rhythm Biosciences Limited ¿Cómo se comparan los beneficios e ingresos de Rhythm Biosciences con su capitalización de mercado? Estadísticas fundamentales de RHY Capitalización bursátil AU$32.32m Beneficios(TTM ) -AU$6.86m Ingresos (TTM ) AU$1.69m
19.1x Ratio precio-ventas (PS)
-4.7x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de RHY Ingresos AU$1.69m Coste de los ingresos AU$3.05m Beneficio bruto -AU$1.36m Otros gastos AU$5.50m Beneficios -AU$6.86m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.028 Margen bruto -80.31% Margen de beneficio neto -405.69% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado RHY a largo plazo?
Ver rendimiento histórico y comparativa
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
